Dimensional Fund Advisors LP Has $15.88 Million Position in ANI Pharmaceuticals, Inc. (ANIP)

Dimensional Fund Advisors LP boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 91.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 339,268 shares of the specialty pharmaceutical company’s stock after purchasing an additional 161,743 shares during the quarter. Dimensional Fund Advisors LP owned 2.92% of ANI Pharmaceuticals worth $15,878,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in ANI Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after purchasing an additional 35,722 shares during the period. First Manhattan Co. grew its holdings in ANI Pharmaceuticals by 35.3% during the second quarter. First Manhattan Co. now owns 376,395 shares of the specialty pharmaceutical company’s stock valued at $17,615,000 after purchasing an additional 98,300 shares during the period. Renaissance Technologies LLC grew its holdings in ANI Pharmaceuticals by 7.0% during the second quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock valued at $13,918,000 after purchasing an additional 19,400 shares during the period. Bank of America Corp DE grew its holdings in ANI Pharmaceuticals by 25.5% during the first quarter. Bank of America Corp DE now owns 197,224 shares of the specialty pharmaceutical company’s stock valued at $9,764,000 after purchasing an additional 40,111 shares during the period. Finally, Northern Trust Corp grew its holdings in ANI Pharmaceuticals by 5.2% during the second quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock valued at $5,285,000 after purchasing an additional 5,599 shares during the period. Hedge funds and other institutional investors own 55.55% of the company’s stock.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Tuesday, November 7th. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Canaccord Genuity restated a “buy” rating on shares of ANI Pharmaceuticals in a report on Thursday, November 2nd. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. ANI Pharmaceuticals has a consensus rating of “Buy” and an average target price of $68.25.

ANI Pharmaceuticals, Inc. (ANIP) opened at $61.90 on Friday. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals, Inc. has a one year low of $42.23 and a one year high of $65.81. The firm has a market cap of $721.32, a P/E ratio of 18.48 and a beta of 2.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. During the same quarter in the previous year, the firm posted $1.09 earnings per share. The business’s revenue was up 25.0% on a year-over-year basis. equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.59 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Has $15.88 Million Position in ANI Pharmaceuticals, Inc. (ANIP)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/dimensional-fund-advisors-lp-has-15-88-million-position-in-ani-pharmaceuticals-inc-anip.html.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply